55% ORR, 73% DCR, and 7.7 month PFS in DKK1-high/PD-L1-high second-line gastric cancer patients DKN-01 also demonstrated preclinical tumor regression data in CRC models supporting ongoing clinical...

Ursa Major, America's only privately funded company that focuses solely on rocket propulsion, will participate in the Deutsche Bank Global Space Summit. Ursa Major Founder and CEO, Joe Laurienti,...

IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that Gross-to-Net (GTN) experts will...

Results demonstrate improved and differentiated effects over first-generation ASK1 inhibitors SEATTLE, Nov. 7, 2022 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company...

Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and bispecific antibodies, today announced new...